Methicillin-Resistant Staphylococcus Aureus Infections | Epidemiology | Mature Markets Data

Publish date: July 2015

Login to access report

Methicillin-Resistant Staphylococcus aureus Epidemiology

DRG Epidemiology's coverage of methicillin-resistant staphylococcus aureus comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the incidence of methicillin-resistant staphylococcus aureus for each country, as well as annualized case counts projected to the national population.

DRG Epidemiology's methicillin-resistant staphylococcus aureus forecast will answer the following questions:

How will changes in the levels of exposure to known risk or protective factors affect the number of methicillin-resistant staphylococcus aureus events per year?

Of all people diagnosed with methicillin-resistant staphylococcus aureus, how many in each country across the major mature pharmaceutical markets are drug-treated?

How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of methicillin-resistant staphylococcus aureus over the forecast period?

All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.

DRG Epidemiology provides at least ten years of forecast data for the following methicillin-resistant staphylococcus aureus patient populations:

Diagnosed MRSA Events by Treatment

Methicillin-Resistant Staphylococcus aureus Diagnosed MRSA Events

Methicillin-Resistant Staphylococcus aureus Diagnosed MRSA Events - BSI

Methicillin-Resistant Staphylococcus aureus Diagnosed MRSA Events - cIAI

Methicillin-Resistant Staphylococcus aureus Diagnosed MRSA Events - cSSSI

Methicillin-Resistant Staphylococcus aureus Diagnosed MRSA Events - HAP

Methicillin-Resistant Staphylococcus aureus Diagnosed MRSA Events - HCAP

Methicillin-Resistant Staphylococcus aureus Diagnosed MRSA Events - Nosocomial Pneumonia

Methicillin-Resistant Staphylococcus aureus Diagnosed MRSA Events - SSI

Methicillin-Resistant Staphylococcus aureus Diagnosed MRSA Events - SSI & cSSSI

… and more (details available on request).

Note: coverage may vary by country and region.

Table of contents

  • Mature Markets Data
    • Introduction
      • Key Findings
      • Overview
        • Hospital-Treated Methicillin-Resistant Staphylococcus Aureus Infection Events by Infection Site, 2016
    • Epidemiology Data
    • Methods
      • Diagnosed Methicillin-Resistant Staphylococcus Aureus Events
      • Diagnosed Methicillin-Resistant Staphylococcus Aureus Events: BSI
      • Diagnosed Methicillin-Resistant Staphylococcus Aureus Events: UTI
      • Diagnosed Methicillin-Resistant Staphylococcus Aureus Events: cIAI
      • Diagnosed Methicillin-Resistant Staphylococcus Aureus Events: NP
      • Diagnosed Methicillin-Resistant Staphylococcus Aureus Events: SSI
      • Diagnosed Methicillin-Resistant Staphylococcus Aureus Events: cSSSI
      • Percentage Drug-Treated
    • Reference Materials
      • Literature Review
      • Risk/Protective Factors
      • Bibliography

Author(s): Devashri Mukherjee, MPH; Lade Ayodele

Research enthusiast with a flair for academic writing, member of the DRG family since April 2015 and working from the India office. Started off career with a bachelor’s in Dental Surgery followed by a master’s in Public health; having primarily worked in the hospital setting as a Research Consultant prior to DRG and with 10 international publications to my credit.

Dr. Ayodele has expertise in forecasting disease populations and is an epidemiology expert in chronic diseases including cancers and cardiovascular diseases, in both the major and emerging pharmaceutical markets. Prior to joining Decision Resources Group, she researched antiretroviral therapy funding, availability and access at the Clinton Foundation Center for Strategic HIV Operations Research. More recently, she was a Medical Innovation and Leadership fellow at Blue Cross Blue Shield of Massachusetts, where she researched and developed strategic plans on health care utilization and quality improvement. Dr. Ayodele holds a Master in Public Health degree (quantitative methods concentration) from Harvard and a medical degree from the University of Ibadan in Nigeria. She is currently pursuing a in epidemiology at Boston University School of Public Health with a focus in pharmacoepidemiology.